Company Profile
GeneOne Life Science, Inc., a biopharmaceutical company provides the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases. Its portfolio also includes GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis, and GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19.
The company's nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA under phase 2 stage for the treatment of SARS-CoV-2. Its portfolio also includes GLS-5100 under pre-clinical stage for prevention of herpes zoster, and GLS-5140 under pre-clinical stage for the treatment of SFTS prophylaxis.
Additionally, it is developing GLS-5300, which is in Phase II clinical trial for MERS. Its portfolio also includes GLS-5700 that is in Phase I clinical trial for Zika, and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C re-infection prophylaxis GLS-6100 that is in pre-clinical stage for hepatitis C prophylaxis. It also's discovery and optimization stage pipeline comprise GLS-7000 for the treatment of breast cancer.
Its portfolio also includes GLS-7100 for treating hemophilia A, GLS-8000 for the prevention of chronic hepatitis B, and GLS-8100 for treating rheumatoid arthritis. Additionally, it engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. Founded in 1976 and headquartered in Seoul, South Korea, GeneOne Life Science was formerly known as VGX International Inc. before rebranding in April 2014.